Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses

Lack of immunogenicity of cancer cells has been considered a major reason for their failure in induction of a tumor specific T cell response. In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li-Xin, Mei, Zhen-Yang, Zhou, Ji-Hao, Yao, Yu-Shi, Li, Yong-Hui, Xu, Yi-Han, Li, Jing-Xin, Gao, Xiao-Ning, Zhou, Min-Hang, Jiang, Meng-Meng, Gao, Li, Ding, Yi, Lu, Xue-Chun, Shi, Jin-Long, Luo, Xu-Feng, Wang, Jia, Wang, Li-Li, Qu, Chunfeng, Bai, Xue-Feng, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650049/
https://www.ncbi.nlm.nih.gov/pubmed/23671644
http://dx.doi.org/10.1371/journal.pone.0062924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650049/
https://www.ncbi.nlm.nih.gov/pubmed/23671644
http://dx.doi.org/10.1371/journal.pone.0062924

Ejemplares similares